Isotretinoína Aurovitas

Isotretinoin, the active ingredient in Isotretinoína Aurovitas, is a retinoid presented as an oral formulation for oral use. It is prescribed for severe recalcitrant nodular acne in patients who have not responded to conventional therapies.

GNH USA supplies Isotretinoína Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isotretinoin is a retinoid used in the management of severe acne.

- Severe recalcitrant nodular acne: reduces existing lesions and prevents formation of new nodules. - Severe cystic acne: diminishes cystic lesions and improves overall skin appearance. - Recalcitrant acne vulgaris: provides clinical improvement when other systemic treatments have failed.

Isotretinoin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dry skin and lips: increased transepidermal water loss. - Elevated liver enzymes: mild, transient hepatic stress. - Hypertriglyceridemia: rise in serum triglyceride levels. - Musculoskeletal discomfort: joint or muscle aches. - Photosensitivity: heightened skin reaction to sunlight. - Mood changes: irritability or mild depressive symptoms.

Serious or Rare Side Effects: - Severe hepatotoxicity: marked elevation of liver function tests. - Pseudotumor cerebri: increased intracranial pressure presenting with headache and visual changes. - Pancreatitis: acute abdominal pain with elevated pancreatic enzymes. - Severe depression or suicidal ideation: requires immediate medical attention. - Teratogenicity: birth defects if exposure occurs during pregnancy. - Severe hyperlipidemia: extreme triglyceride elevations risking pancreatitis.

Before initiating therapy, clinicians should evaluate baseline laboratory values and consider patient-specific risk factors. - Pregnancy testing: confirm negative test before starting and use effective contraception throughout treatment. - Liver function monitoring: check ALT/AST at baseline and periodically during therapy. - Lipid profile assessment: obtain fasting triglycerides and cholesterol before and during treatment. - Mood evaluation: monitor for depressive symptoms or suicidal thoughts. - Ophthalmologic review: assess for visual disturbances suggestive of intracranial hypertension. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Isotretinoin can interact with several medications, altering efficacy or safety.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive teratogenic risk and hypervitaminosis A. - Systemic corticosteroids: may exacerbate mood disturbances.

Moderate Interactions (Monitor Closely): - Oral contraceptives: potential reduction in efficacy; consider alternative non‑hormonal methods. - Anticonvulsants (e.g., phenobarbital, phenytoin): may lower isotretinoin plasma levels. - Lipid‑lowering agents (e.g., fibrates): monitor triglyceride levels closely.